血清BDNF、GDNF、DCN、NRG-1与精神分裂症患者病情进展、认知功能及临床疗效的关系研究  

A study of the relationship between serum BDNF,GDNF,DCN,and NRG-1 and disease progression,cognitive function,and clinical efficacy in patients with schizophrenia

作　　者：杜颖 李旭丹 张士巧 马占平 Du Ying;Li Xudan;Zhang Shiqiao;et al(Department of Psychiatry,Hengshui Seventh People's Hospital,Hengshui 053000,China)

机构地区：[1]衡水市第七人民医院精神科,053000 [2]衡水市第七人民医院心理一科,053000

出　　处：《中华保健医学杂志》2025年第1期94-98,共5页Chinese Journal of Health Care and Medicine

基　　金：河北省中医药管理局科技计划项目(2020541)。

摘　　要：目的探讨血清脑源性神经营养因子(BDNF)、胶质源性神经营养因子(GDNF)、核心蛋白多糖(DCN)、神经调节蛋白-l(NRG-l)与精神分裂症患者病情进展、认知功能及临床疗效的关系。方法前瞻性选取衡水市第七人民医院2020年9月~2023年5月精神分裂症患者282例,所选患者均接受奥氮平片联合改良电休克治疗,均治疗2个月。依据治疗效果和病情将患者再进行亚组分析。另外选取同期于本院进行健康体检的健康人群290名作为健康对照组。比较观察组和健康对照组、不同病情及不同临床疗效精神分裂症血清指标水平,对比观察组和健康对照组认知功能,并分析血清指标水平与精神分裂症患者病情进展、认知功能的相关性。结果观察组血清BDNF、GDNF、DCN、NRG-1水平[(2.53±0.79)μg∕L、(411.22±40.90)ng∕L、(2.15±0.64)ng∕ml、(9.76±2.65)pg∕ml]低于健康对照组[(10.16±2.75)μg∕L、(581.33±112.43)ng∕L、(6.32±1.75)ng∕mL、(34.87±9.22)pg∕mL],差异有统计学意义(t=44.828、67.688、37.641、44.000,P<0.05)。观察组患者语义流畅性、言语记忆、视觉记忆、符合编码评分[(15.32±4.41)分、(41.04±9.21)分、(15.32±4.10)分、(40.34±8.87)分]低于健康对照组[(23.69±6.71)分、(63.83±11.32)分、(29.54±8.43)分、(65.21±10.04)分],连线测验评分(53.78±10.46)分高于健康对照组(32.17±5.59)分,差异有统计学意义(t=17.578、26.370、25.541、31.364、30.932,P<0.05)。阳性与阴性症状量表(PANSS)高分组血清BDNF、GDNF、DCN、NRG-1水平[(1.97±0.56)μg∕L、(310.34±27.56)ng∕L、(1.22±0.40)ng∕ml、(6.03±1.20)pg∕ml]低于PANSS低分组[(3.08±1.02)μg∕L、(512.09±54.23)ng∕L、(3.08±0.88)ng∕mL、(13.49±4.09)pg∕mL],差异有统计学意义(t=11.062、38.383、22.122、20.066,P<0.05)。血清BDNF、GDNF、DCN、NRG-1水平在痊愈组、显效组、有效组、无效组之间呈递减趋势(F=203.490、20.376、73.517、106.249,P<0.05)。血清BDNF、Objective To investigate the relationship between serum brain-derived neurotrophic factor(brain-derived neurotrophic factor,BDNF),glial-derived neurotrophic factor(glial-derived neurotrophic factor,GDNF),decorin(decorin,DCN),and neuromodulin-l(neuromodulin-l,NRG-l)and the progression of disease,cognitive function,and clinical efficacy in patients with schizophrenia.Methods 282 patients with schizophrenia were forward-looking selected as the study group,the cases were enrolled from September 2020 to May 2023,and the collection site was the Seventh People's Hospital of Hengshui City,and the selected patients were treated with olanzapine tablets combined with modified electroconvulsive therapy for 2 months,and patients were reanalyzed into subgroups based on treatment outcome and condition.In addition,290 healthy people who underwent health checkups in our hospital during the same period were selected as the control group.The levels of serum indicator of schizophrenia in the study group and control group,different conditions and different clinical efficacy were compared,and the cognitive functions of the study group and control group were compared,and the correlation between levels of serum indicator and the progression of the condition and the correlation of patients with schizophrenia were analyzed.Results Levels of serum BDNF,GDNF,DCN,NRG-1 of the study group[(2.53±0.79)μg∕L,(411.22±40.90)ng∕L,(2.15±0.64)ng∕ml,(9.76±2.65)pg∕ml]were lower than those of the control group[(10.16±2.75)μg∕L,(581.33±112.43)ng∕L,(6.32±1.75)ng∕ml,(34.87±9.22)pg∕ml(t=44.828,67.688,37.641,44.000,P<0.05).The scores of semantic fluency,verbal memory,visual memory,and conformity coding of the study group[(15.32±4.41)points,(41.04±9.21)points,(15.32±4.10)points,(40.34±8.87)points]were lower than those of the control group[(23.69±6.71)points,(63.83±11.32)points,(29.54±8.43)points,(65.21±10.04)points](t=17.578,26.370,25.541,31.364,P<0.05),and the scores of the connectivity test[(53.78±10.46)points]were higher t

关 键 词：精神分裂症 脑源性神经营养因子 胶质源性神经营养因子 核心蛋白多糖 神经调节蛋白-l 

分 类 号：R749[医药卫生—神经病学与精神病学]